Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites.
Sera from dogs naturally infected with Leishmania infantum were analysed for the IgG subclass specificity of their antibody response by ELISA. Dogs infected with L. infantum produced both IgG1 and IgG2 antibodies with IgG2 being associated with asymptomatic infections and IgG1 being associated with disease (symptomatic dogs, non- or low-responsive to chemotherapy). The differential responses of IgG1 and IgG2 serum antibodies in asymptomatic and symptomatic dogs may indicate a dichotomous immune response to infection with L. infantum. To confirm this, on a broader scale, sera from dogs naturally exposed to an asymptomatic protozoan infection, Toxoplasma gondii, were also analysed as were sera from dogs exposed to the helminths, Dirofilaria immitis and Toxocara canis. Antibodies specific for T. gondii antigen detected in sera from 17 dogs were of the IgG2 subclass only. Both IgG1 and IgG2 antibodies to D. immitis and T. canis were present in the sera of naturally infected dogs but IgG1 appeared to be the predominant subclass. Furthermore, in dogs experimentally infected with T. canis, selective regulation of IgG2 and IgG1 responses was apparent since production of the two subclasses occurred at different times following infection, with IgG2 levels declining as IgG1 levels rose. Thus, the analysis of IgG subsets in parasitized dogs provides evidence of a dichotomous response to infection: IgG2 is associated with asymptomatic protozoan infections and IgG1 is associated with helminth infections and disease caused by protozoan infection.
Deplazes
P
P
Institute of Parasitology, University of Zurich, Switzerland.
Smith
N C
NC
Arnold
P
P
Lutz
H
H
Eckert
J
J
D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis / Q000097:blood; D000913:Antibodies, Protozoan / Q000096:biosynthesis* / Q000097:blood; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004183:Dirofilaria immitis / Q000276:immunology; D004184:Dirofilariasis / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology*; D004285:Dogs; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000097:blood; D018314:Leishmania infantum / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D014124:Toxoplasmosis, Animal / Q000276:immunology
D000909:Antibodies, Helminth; D000913:Antibodies, Protozoan; D000981:Antiprotozoal Agents; D007074:Immunoglobulin G; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate